Opinion

Video

Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes

Anjali Tiku Owens, MD, examines mavacamten, the pioneering cardio myosin inhibitor (CMI) approved for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), which is exclusively accessible through the restricted Risk Evaluation and Mitigation Strategy (REMS) program; the KOL delves into the objectives of this program and how it strives to enhance medication safety and optimize patient outcomes.

  1. Mavacamten is the first approved CMI for oHCM and is only available through the restricted Risk Evaluation and Mitigation Strategy (REMS) program. What is the purpose of this program, and how does it aim to improve medication safety and patient outcomes?
  2. How does your institution/clinic handle the execution of the REMS program for mavacamen, how do you get certified, what are the institutional protocols?

Related Videos
Understanding Angioedema in Urticaria, with Jonathan Bernstein, MD
Identifying B-cell Depleting Agents for Lupus Nephritis, with Richard Furie, MD
Brian Lee, MD | Credit: AASLD
Transformations in Aortic Disease Management with Mehrdad Ghoreishi, MD | Image Credit: Baptist Health South Florida
Importance of Birch Triterpene Findings for Epidermolysis Bullosa, with Anna Bruckner, MD
Phase 3 Findings on Birch Triterpenes for Epidermolysis Bullosa, with Anna Bruckner, MD
© 2025 MJH Life Sciences

All rights reserved.